UBS Group Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $72.00
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective upped by analysts at UBS Group from $65.00 to $72.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 87.50% from the stock’s current price. Several […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective upped by analysts at UBS Group from $65.00 to $72.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 87.50% from the stock’s current price. Several […]
